Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review
Metadata
Show full item recordEditorial
MDPI
Materia
Colorectal cancer Capecitabine Pharmacogenetics Single nucleotide polymorphism Cancers
Date
2023-03-17Referencia bibliográfica
Cura, Y.; Pérez-Ramírez, C.; Sánchez-Martín, A.; Membrive-Jimenez, C.; Valverde-Merino, M.I.; González-Flores, E.; Morales, A.J. Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review. Cancers 2023, 15, 1821. [https://doi.org/10.3390/cancers15061821]
Sponsorship
Co-funded by ERDF funds (EU) from the Instituto de Salud Carlos III (PT13/0010/0039).Abstract
The aim of this systematic review was to provide a comprehensive overview of the literature
published in the last decade on the association of single-nucleotide polymorphisms in genes involved
in the pharmacodynamic and pharmacokinetic pathways of capecitabine with treatment outcomes
among colorectal cancer patients. A systematic search of the literature published in the last 10 years
was carried out in two databases (Medline and Scopus) using keywords related to the objective.
Quality assessment of the studies included was performed using an assessment tool derived from
the Strengthening the Reporting of Genetic Association (STREGA) statement. Thirteen studies
were included in this systematic review. Genes involved in bioactivation, metabolism, transport,
mechanism of action of capecitabine, DNA repair, and folate cycle were associated with toxicity.
Meanwhile, genes related to DNA repair were associated with therapy effectiveness. This systematic
review reveals that several SNPs other than the four DPYD variants that are screened in clinical
practice could have an impact on treatment outcomes. These findings suggest the identification of
future predictive biomarkers of effectiveness and toxicity in colorectal cancer patients treated with
capecitabine. However, the evidence is sparse and requires further validation